Researchers try new ways of preserving more hearts for transplants
The new research aims to overcome barriers to using organs from someone who dies when their heart stops. Called DCD, or donation after circulatory death, it involves a controversial recovery technique or the use of expensive machines.
Surgeons at Duke and Vanderbilt universities reported Wednesday that they've separately devised simpler approaches to retrieve those hearts. In the New England Journal of Medicine, they described successfully transplanting hearts to a 3-month-old infant at Duke and three men at Vanderbilt.
3 Two university hospitals are pioneering new ways to expand lifesaving heart transplants for adults and babies.
Africa Studio – stock.adobe.com
'These DCD hearts work just as well as hearts from brain-dead donors,' said Vanderbilt lead author Dr. Aaron M. Williams.
How hearts are saved for donation
Most transplanted hearts come from donors who are brain-dead. In those situations, the body is left on a ventilator that keeps the heart beating until the organs are removed.
Circulatory death occurs when someone has a nonsurvivable brain injury, but because all brain function hasn't ceased, the family decides to withdraw life support, and the heart stops. That means organs can spend a while without oxygen before being recovered, a time lag usually doable for kidneys and other organs, but that can raise questions about the quality of hearts.
To counter damage and determine whether DCD organs are usable, surgeons can pump blood and oxygen to the deceased donor's abdominal and chest organs after clamping off access to the brain. But it's ethically controversial to artificially restore circulation even temporarily, and some hospitals prohibit that technique, called normothermic regional perfusion, or NRP.
3 Called DCD, or donation after circulatory death, the new methods involve a controversial recovery technique or the use of expensive machines.
AP
Another option is to 'reanimate' DCD organs in a machine that pumps blood and nutrients on the way to the transplant hospital. The machines are expensive and complex, and Duke's Dr. Joseph Turek said the devices can't be used for young children's small hearts — the age group with the most dire need.
New ways of preserving hearts
Turek's team found a middle ground: Remove the heart and attach some tubes of oxygen and blood to briefly assess its ability to function, not in a machine but on a sterile table in the operating room.
They practiced with piglets. Then came the real test. At another hospital, life support was about to be withdrawn from a 1-month-old whose family wanted to donate — and who would be a good match for a 3-month-old Duke patient in desperate need of a new heart. The other hospital didn't allow the controversial NRP recovery technique but let Turek's team test the experimental alternative.
It took just five minutes to tell 'the coronary arteries are filling well, it's pink, it's beating,' Turek said. The team promptly put the little heart on ice and raced it back to Duke.
Vanderbilt's system is even simpler: Infuse the heart with a nutrient-rich, cold preservative solution before removing it from the donor's body, similar to how hearts from brain-dead donors are handled.
That 'replenishes the nutrients that are depleted during the dying process and helps protect it for transport,' Williams explained, adding that Vanderbilt has performed about 25 such transplants so far. 'Our view is you don't necessarily need to reanimate the heart.'
More donated hearts are needed
There's a huge need for more transplantable hearts. Hundreds of thousands of adults suffer from advanced heart failure, yet many are never even offered a transplant because of the organ shortage.
Every year, about 700 children in the U.S. are added to the transplant list for a new heart, and about 20% die waiting. Turek said infants are at particular risk.
Last year, people whose lives ended via circulatory death made up 43% of the nation's deceased donors, but just 793 of the 4,572 heart transplants.
3 Hundreds of thousands of adults suffer from advanced heart failure, yet many are never even offered a transplant because of the organ shortage, according to reports.
Robert Kneschke – stock.adobe.com
That's why many specialists say finding ways to use more of those hearts is crucial. The new studies are small and early-stage but promising, said Brendan Parent of NYU Langone Health, who directs transplant ethics and policy research.
'Innovation to find ways to recover organs successfully after circulatory death are essential for reducing the organ shortage,' he said.
If alternatives pan out, 'I absolutely think that cardiac programs will be thrilled, especially at hospitals that have rejected NRP.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
A type of HPV can cause skin cancer in people with weakened immune systems, report finds
Doctors at the National Institutes of Health have discovered a new cause of skin cancer, according to a case report published Wednesday in the New England Journal of Medicine. The culprit is a type of human papillomavirus (HPV) that's regularly found on the skin. It's long been thought to play a role in the development of skin cancer, but wasn't believed to be a direct cause. Skin cancer is caused by DNA damage in skin cells. The most common source of that damage is ultraviolet radiation from the sun. HPV can help UV-damaged DNA build up in cells and turn cancerous. However, in the new case report, doctors found that the virus itself could cause cancerous lesions to form. The discovery was made in a 34-year-old woman with a weakened immune system; experts said it's highly unlikely that HPV could play the same role in causing skin cancer in a person with a healthy immune system. 'The virus replicated in a somewhat uncontrolled manner and ended up integrating into the skin cells and once they did that, they became cancerous,' said Dr. Andrea Lisco, section chief of the mucosal and cutaneous viral immunopathogenesis unit at the National Institute of Allergy and Infectious Diseases, part of the NIH. Lisco was the woman's doctor and also the senior author of the case report. The woman had 43 spots of cutaneous squamous cell carcinoma — the second-most common type of skin cancer, after melanoma — on her face, hands and legs. She had surgery to remove the cancers and immunotherapy, but the cancer returned. When Lisco and his team biopsied several of her new tumors, they found that the woman's skin cancer was being driven by something they hadn't seen before: a group of HPVs called beta HPV. About 90% of people carry a strain of beta HPV. Usually, the virus lives on the skin and doesn't integrate into the DNA of skin cells. 'We shake hands and we pick up those viruses, but if our immune systems are under control, we are fine,' Lisco said. It's a different group of HPV strains — alpha HPVs — that are linked to a range of cancers. Alpha HPVs live on mucus membranes and can integrate into DNA, causing cancers of the cervix, anus, head and neck. The woman in the case report had a genetic condition that weakened her T-cells (a type of immune cell), leaving her immunocompromised. This allowed the beta HPV living on her skin to behave more like alpha HPV, integrating its DNA into her skin cells and replicating undisturbed, turning the cells cancerous. 'You don't know how much you can directly apply the information from one patient to the wide variety of patients,' said Dr. Anthony Oro, professor of dermatology at Stanford Medicine, who wasn't involved in the case. However, 'it suggests that, in the event that the T-cell arm of the immune system is not doing its job, beta-type HPV viruses could contribute to skin cancer, and maybe other kinds of cancers as well,' he said. The patient needed a stem cell transplant, which replaced her defective T-cells with T-cells that could prevent the HPV from replicating. 'We needed to give this patient a whole new immune system,' Lisco said. It worked. Three years post-transplant, the woman's skin cancer has not returned. 'It gives us good information about how the interplay of the HPV and the immune system works,' said Dr. Anthony Rossi, a dermatologist and Mohs surgeon at Memorial Sloan Kettering Cancer Center, who also wasn't involved with the woman's case. Doctors have known for a long time that some beta HPVs cause changes on the skin, such as warts on the hands and feet. 'HPV can integrate and cause changes in the cell cycle, especially in people with suppressed immune systems,' Rossi said. 'What was novel about this is that they found out it was a beta HPV that integrated into the DNA.' Other researchers have speculated this was a possibility based on studies in mice, but the new report shows that it can occur in humans. How many people could be at risk is still unknown. 'This is just one patient, and they have this unique situation of an immunological condition that enables the beta HPV to replicate unchecked,' Oro said. Other biopsies of squamous skin cancers have not detected HPV, meaning not all cases are caused by the viruses. Lisco said that the original notion — that HPV passively contributes to cutaneous squamous cell carcinoma by helping UV radiation damage skin cells, but doesn't actively help cancer grow — is still the likely explanation for many people. For them, 'protection from UV would be the prevention,' Lisco said — wearing sunscreen and covering up your skin from the sun — adding that immunocompromised people should be monitored more closely. People with weakened immune systems are as much as 100 times more likely to develop squamous cell carcinoma. The Gardasil HPV vaccine protects against nine strains of alpha HPV and has been shown to lower rates of cervical and head and neck cancers. It's unclear how much cross-protection, if any, the vaccine provides against other strains of HPV, including beta HPV. 'Even if this strain is not in the vaccine, there is some theory that there is cross-talk between HPV strains,' Rossi said. Most people will get HPV in their lifetimes. Scientists have so far identified about 200 unique strains of the virus. Alpha-HPV, with its well-established links to cancer, has thus far been the primary subject of research. 'This suggests that this other side of the family might also be important in situations where our immune system is not doing its job,' Oro said. This article was originally published on Solve the daily Crossword
a day ago
Ousted vaccine panel members say rigorous science is being abandoned
NEW YORK -- The 17 experts who were ousted from a government vaccine committee last month say they have little faith in what the panel has become, and have outlined possible alternative ways to make U.S. vaccine policy. U.S. Health Secretary Robert F. Kennedy Jr. abruptly fired the entire Advisory Committee on Immunization Practices, accusing them of being too closely aligned with manufacturers and of rubber-stamping vaccines. He handpicked replacements that include several vaccine skeptics. In a commentary published Wednesday in the New England Journal of Medicine, the former panel members wrote that Kennedy — a leading voice in the anti-vaccine movement before becoming the U.S. government's top health official — and his new panel are abandoning rigorous scientific review and open deliberation. That was clear, they said, during the new panel's first meeting, in June. It featured a presentation by an anti-vaccine advocate that warned of dangers about a preservative used in a few flu vaccines, but the committee members didn't hear from Centers for Disease Control and Prevention staffers about an analysis that concluded there was no link between the preservative and neurodevelopmental disorders. The new panel recommended that the preservative, thimerosal, be removed even as some members acknowledged there was no proof it was causing harm. 'That meeting was a travesty, honestly,' said former ACIP member Dr. Yvonne Maldonado, a pediatric infectious diseases expert at Stanford University. The 17 discharged experts last month published a shorter essay in the Journal of the American Medical Association that decried Kennedy's 'destabilizing decisions." The focus was largely on their termination and on Kennedy's decision in May to stop recommending COVID-19 vaccines for healthy children and pregnant women. In the new commentary, the ousted committee members took it one step further and prescribed some steps that could be taken to maintain scientifically sound vaccine recommendations. 'An alternative to the Committee should be established quickly and — if necessary — independently from the federal government," they wrote. 'No viable pathway exists to fully replace the prior trusted and unbiased ACIP structure and process. Instead, the alternatives must focus on limiting the damage to vaccination policy in the United States.' Options included having professional organizations working together to harmonize vaccine recommendations or establishing an external auditor of ACIP recommendations. There are huge challenges to the ideas, including having access to the best data, the authors acknowledged. There's also the question of whether health insurers would pay for vaccinations that are recommended by alternative groups but not ACIP. They might pick and choose which vaccines to cover, said the University of North Carolina's Noel Brewer, another former ACIP member. For example, they might pay for vaccines that offer more immediate cost savings for health care, like the flu vaccine. 'But maybe not ones that have a longer-term benefit like HPV vaccine,' which is designed to prevent futures cancers, Brewer said. Officials with the U.S. Department of Health and Human Services did not immediately respond to a request for comment. ___
NBC News
a day ago
- NBC News
Report describes new cause of skin cancer
Doctors at the National Institutes of Health have discovered a new cause of skin cancer, according to a case report published Wednesday in the New England Journal of Medicine. The culprit is a type of human papillomavirus (HPV) that's regularly found on the skin. It's long been thought to play a role in the development of skin cancer, but wasn't believed to be a direct cause. Skin cancer is caused by DNA damage in skin cells. The most common source of that damage is ultraviolet radiation from the sun. HPV can help UV-damaged DNA build up in cells and turn cancerous. However, in the new case report, doctors found that the virus itself could cause cancerous lesions to form. The discovery was made in a 34-year-old woman with a weakened immune system; experts said it's highly unlikely that HPV could play the same role in causing skin cancer in a person with a healthy immune system. 'The virus replicated in a somewhat uncontrolled manner and ended up integrating into the skin cells and once they did that, they became cancerous,' said Dr. Andrea Lisco, section chief of the mucosal and cutaneous viral immunopathogenesis unit at the National Institute of Allergy and Infectious Diseases, part of the NIH. Lisco was the woman's doctor and also the senior author of the case report. The woman had 43 spots of cutaneous squamous cell carcinoma — the second-most common type of skin cancer, after melanoma — on her face, hands and legs. She had surgery to remove the cancers and immunotherapy, but the cancer returned. When Lisco and his team biopsied several of her new tumors, they found that the woman's skin cancer was being driven by something they hadn't seen before: a group of HPVs called beta HPV. About 90% of people carry a strain of beta HPV. Usually, the virus lives on the skin and doesn't integrate into the DNA of skin cells. 'We shake hands and we pick up those viruses, but if our immune systems are under control, we are fine,' Lisco said. It's a different group of HPV strains — alpha HPVs — that are linked to a range of cancers. Alpha HPVs live on mucus membranes and can integrate into DNA, causing cancers of the cervix, anus, head and neck. The woman in the case report had a genetic condition that weakened her T-cells (a type of immune cell), leaving her immunocompromised. This allowed the beta HPV living on her skin to behave more like alpha HPV, integrating their DNA into her skin cells and replicating undisturbed, turning the cells cancerous. 'You don't know how much you can directly apply the information from one patient to the wide variety of patients,' said Dr. Anthony Oro, professor of dermatology at Stanford Medicine, who wasn't involved in the case. However, 'it suggests that, in the event that the T-cell arm of the immune system is not doing its job, beta-type HPV viruses could contribute to skin cancer, and maybe other kinds of cancers as well,' he said. The patient needed a stem cell transplant, which replaced her defective T-cells with T-cells that could prevent the HPV from replicating. 'We needed to give this patient a whole new immune system,' Lisco said. It worked. Three years post-transplant, the woman's skin cancer has not returned. 'It gives us good information about how the interplay of the HPV and the immune system works,' said Dr. Anthony Rossi, a dermatologist and Mohs surgeon at Memorial Sloan Kettering Cancer Center, who also wasn't involved with the woman's case. Doctors have known for a long time that some beta HPVs cause changes on the skin, such as warts on the hands and feet. 'HPV can integrate and cause changes in the cell cycle, especially in people with suppressed immune systems,' Rossi said. 'What was novel about this is that they found out it was a beta HPV that integrated into the DNA.' Other researchers have speculated this was a possibility based on studies in mice, but the new report shows that it can occur in humans. How many people could be at risk is still unknown. 'This is just one patient, and they have this unique situation of an immunological condition that enables the beta HPV to replicate unchecked,' Oro said. Other biopsies of squamous skin cancers have not detected HPV, meaning not all cases are caused by the viruses. Lisco said that the original notion — that HPV passively contributes to cutaneous squamous cell carcinoma by helping UV radiation damage skin cells, but doesn't actively help cancer grow — is still the likely explanation for many people. For them, 'protection from UV would be the prevention,' Lisco said — wearing sunscreen and covering up your skin from the sun — adding that immunocompromised people should be monitored more closely. People with weakened immune systems are as much as 100 times more likely to develop squamous cell carcinoma. The Gardasil HPV vaccine protects against nine strains of alpha HPV and has been shown to lower rates of cervical and head and neck cancers. It's unclear how much cross-protection, if any, the vaccine provides against other strains of HPV, including beta HPV. 'Even if this strain is not in the vaccine, there is some theory that there is cross-talk between HPV strains,' Rossi said. Most people will get HPV in their lifetimes. Scientists have so far identified about 200 unique strains of the virus. Alpha-HPV, with its well-established links to cancer, has thus far been the primary subject of research. 'This suggests that this other side of the family might also be important in situations where our immune system is not doing its job,' Oro said.
